|کد مقاله||کد نشریه||سال انتشار||مقاله انگلیسی||ترجمه فارسی||نسخه تمام متن|
|5670989||1408037||2018||3 صفحه PDF||ندارد||دانلود کنید|
IntroductionThe aim of this study was to assess the efficacy of artesunate-amodiaquine (ASÂ +Â AQ) which is the first-line treatment for uncomplicated falciparum malaria in Eritrea.Materials and methodsThe study was conducted from December 2014 to March 2015 in Ghindae Zonal Referral Hospital in Northern Red Sea Zone. Out of 481 patients screened, 103 were enrolled in the study. The therapeutic efficacy test was done as per the WHO protocol for a period of 28Â days of follow-up.ResultsThe PCR-uncorrected treatment outcome was classified as adequate clinical and parasitological response (ACPR) in 95 patients, which meant the cure rate was 96.0 (95% CI: 89.7%â98.5%) after survival analysis.ConclusionsTherapeutic efficacy of ASÂ +Â AQ still meets the WHO efficacy criteria for its continued use in the study area as the first-line drug against uncomplicated falciparum malaria. However, further studies are needed using correction with molecular markers to monitor therapeutic efficacy of antimalarial drugs in this area.
Journal: Acta Tropica - Volume 177, January 2018, Pages 94-96